Open AccessSevere hypercalcemia due to teriparatide
Author(s) -
Cumali Karatoprak,
Kadir Kayataş,
Hanifi Kilicaslan,
Servet Yolbaş,
Nurhan Aliye Yazimci,
Tolga Gümüskemer,
Refik Demirtunç
Publication year - 2012
Publication title -
indian journal of pharmacology/the indian journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.286
H-Index - 59
eISSN - 1998-3751
pISSN - 0253-7613
DOI - 10.4103/0253-7613.93869
Subject(s) - teriparatide , osteoporosis , medicine , bone resorption , parathyroid hormone , endocrinology , bone density conservation agents , anabolism , bone mineral , calcium
Osteoporosis that is by far the most common metabolic bone disease, has been defined as a skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Anabolic therapy with teriparatide, recombinant human parathyroid hormone (PTH 1-34), stimulates bone formation and resorption and improves trabecular and cortical microarchitecture. Teriparatide is indicated for the treatment of men and postmenopausal women with osteoporosis who are at high risk for fracture, including those who have failed or are intolerant of previous osteoporosis therapy. In conclusion, although teriparatide seems quite effective in the treatment of osteoporosis, it may cause life-threatening hypercalcemia. Therefore, patients should be closely monitored if symptoms of hypercalcemia are present during teriparatide treatment. Sustained hypercalcemia due to teriparatide treatment can not be seen in literature so we wanted to emphasize that severe hypercalcemia may develop due to teriperatide.